AbCellera Biologics Inc (ABCL) Actualités

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call...

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th...

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AbCellera Reports Q3 2024 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is...

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Stifel...

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation on its T-cell engager platform at the SITC 39th Annual Meeting, to be...